

Table 10.1

Kaposi Sarcoma

Number of Cases

By SEER Location and Year of Diagnosis, 1975-2007

All Races, Males, All Ages

Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007
SEER 9 ^b	134	79	326	888	1,573	2,130	2,233	2,057	1,801	839	390	399	331	362	316
SEER 9 except SF-Oakland	102	44	85	260	427	775	842	976	874	463	243	265	221	241	224
San Francisco- Oakland SMSA ^c	32	35	241	628	1,146	1,355	1,391	1,081	927	376	147	134	110	121	92
San Francisco City/County	15	21	201	540	955	1,076	1,089	792	690	253	86	79	69	79	59

Age-Adjusted Cancer Incidence Rates^a

By SEER Location and Year of Diagnosis, 1975-2007

All Races, Males, All Ages

Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007
SEER 9 ^b	0.4	0.5	1.7	4.2	7.1	9.2	9.3	8.2	7.0	3.2	1.5	1.5	1.3	1.4	1.2
SEER 9 except SF-Oakland	0.4	0.4	0.6	1.5	2.3	4.0	4.2	4.6	4.0	2.1	1.1	1.2	1.0	1.1	1.0
San Francisco- Oakland SMSA ^c	0.7	1.3	7.0	17.2	30.0	33.9	34.0	25.6	22.0	8.9	3.5	3.0	2.6	2.7	2.1
San Francisco City/County	1.1	3.1	25.1	65.3	111.3	124.5	125.7	89.1	77.5	28.2	9.4	8.5	7.4	8.0	6.0

^a Rates are per 100,000 males and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).^b The SEER 9 areas are San Francisco-Oakland SMSA, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.^c The San Francisco-Oakland SMSA represents 15% of all persons in the SEER areas. For this age group, all SEER areas may not be generalizable to the United States for Kaposi Sarcoma.

- Statistic not shown. Rate based on less than 4 cases for the time interval.

Table 10.2
Kaposi Sarcoma

Number of Cases

By SEER Location and Year of Diagnosis, 1975-2007

All Races, Males, Ages 20-54

SEER Location	Year of Diagnosis														
	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007
SEER 9 ^b	13	26	254	806	1,480	1,993	2,104	1,922	1,676	754	317	345	258	302	254
SEER 9 except SF-Oakland	11	5	35	207	378	694	773	910	809	410	196	226	182	198	186
San Francisco- Oakland SMSA ^c	<4	21	219	599	1,102	1,299	1,331	1,012	867	344	121	119	76	104	68
San Francisco City/County	<4	18	193	520	924	1,040	1,051	748	649	236	76	73	52	71	50

Age-Adjusted Cancer Incidence Rates^a

By SEER Location and Year of Diagnosis, 1975-2007

All Races, Males, Ages 20-54

SEER Location	Year of Diagnosis														
	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007
SEER 9 ^b	0.1	0.3	2.4	7.4	13.1	16.9	17.1	14.9	12.7	5.6	2.3	2.5	1.9	2.2	1.8
SEER 9 except SF-Oakland	0.1	0.1	0.4	2.2	3.9	6.9	7.4	8.4	7.2	3.6	1.7	2.0	1.6	1.7	1.6
San Francisco- Oakland SMSA ^c	-	1.3	12.1	32.3	57.3	64.4	63.9	46.8	40.2	15.8	5.4	5.2	3.3	4.6	3.0
San Francisco City/County	-	5.3	47.8	125.1	214.0	238.8	240.3	165.3	142.7	51.5	16.1	15.4	10.5	14.1	10.0

^a Rates are per 100,000 males aged 20-54 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b The SEER 9 areas are San Francisco-Oakland SMSA, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

^c The San Francisco-Oakland SMSA represents 15% of all persons in the SEER areas. For this age group, all SEER areas may not be generalizable to the United States for Kaposi Sarcoma.

- Statistic not shown. Rate based on less than 4 cases for the time interval.

Table 10.3

Kaposi Sarcoma

Number of Cases

By SEER Location and Year of Diagnosis, 1975-2007

All Races, Males, Ages 55+

Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007
SEER 9 ^b	121	53	71	81	92	135	129	134	125	85	73	53	73	59	62
SEER 9 except SF-Oakland	91	39	49	53	49	81	69	65	65	53	47	38	39	42	38
San Francisco- Oakland SMSA ^c	30	14	22	28	43	54	60	69	60	32	26	15	34	17	24
San Francisco City/County	14	<4	8	20	31	35	38	44	41	17	10	6	17	8	9

Age-Adjusted Cancer Incidence Rates^a

By SEER Location and Year of Diagnosis, 1975-2007

All Races, Males, Ages 55+

Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007
SEER 9 ^b	1.9	1.9	2.4	2.4	2.5	3.6	3.6	3.3	3.0	2.1	1.7	1.3	1.5	1.2	1.1
SEER 9 except SF-Oakland	1.7	1.7	2.0	2.0	1.8	2.7	2.4	2.0	1.9	1.6	1.3	1.1	1.0	1.0	0.9
San Francisco- Oakland SMSA ^c	2.9	3.1	4.6	4.7	6.4	8.1	9.6	10.4	8.8	4.8	3.7	2.1	4.4	2.1	2.7
San Francisco City/County	4.7	-	5.6	12.9	20.5	23.5	26.4	30.5	29.0	11.5	6.7	3.8	10.2	4.4	4.7

^a Rates are per 100,000 males aged 55+ and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).^b The SEER 9 areas are San Francisco-Oakland SMSA, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.^c The San Francisco-Oakland SMSA represents 15% of all persons in the SEER areas. For this age group, all SEER areas may not be generalizable to the United States for Kaposi Sarcoma.

- Statistic not shown. Rate based on less than 4 cases for the time interval.

Table 10.4
Kaposi Sarcoma

Age-adjusted SEER Incidence^a Rates by Year, Race and Sex

Year of Diagnosis:	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
1975	0.23	0.56	-	0.22	0.56	-	-	-	-
1976	0.25	0.47	-	0.24	0.48	-	-	-	-
1977	0.29	0.54	-	0.30	0.55	-	-	-	-
1978	0.24	0.35	0.17	0.23	0.34	-	-	-	-
1979	0.18	0.30	-	0.18	0.30	-	-	-	-
1980	0.28	0.56	-	0.30	0.60	-	-	-	-
1981	0.31	0.54	-	0.34	0.61	-	-	-	-
1982	0.65	1.20	0.18	0.71	1.32	0.18	-	-	-
1983	1.07	2.19	-	1.19	2.40	-	-	-	-
1984	1.81	3.59	-	1.99	3.91	-	1.27	2.89	-
1985	2.46	4.86	0.16	2.80	5.48	0.18	1.09	2.24	-
1986	3.27	6.54	-	3.71	7.34	-	1.65	3.59	-
1987	3.80	7.61	-	4.25	8.44	-	2.09	4.29	-
1988	4.41	8.85	0.15	4.81	9.54	0.15	3.40	7.28	-
1989	4.76	9.52	0.14	5.13	10.17	-	4.57	9.68	-
1990	4.61	9.21	0.18	5.04	9.99	0.15	3.65	7.54	-
1991	4.70	9.40	0.19	5.04	10.00	0.18	4.59	9.54	-
1992	4.38	8.69	0.18	4.60	9.02	0.18	4.97	10.48	-
1993	3.86	7.64	0.17	4.05	7.96	0.15	4.28	8.59	-
1994	3.79	7.47	0.17	3.88	7.59	0.13	4.15	8.42	-
1995	3.29	6.45	0.20	3.28	6.37	0.17	4.90	10.19	-
1996	2.23	4.40	0.16	2.01	3.99	-	4.61	9.09	-
1997	1.08	2.09	0.13	0.91	1.78	-	2.67	5.31	-
1998	0.81	1.57	-	0.69	1.31	-	1.79	3.78	-
1999	0.78	1.47	0.14	0.66	1.24	-	1.94	3.72	-
2000	0.80	1.55	-	0.67	1.30	-	1.98	4.00	-
2001	0.82	1.48	0.18	0.66	1.18	0.15	1.94	3.79	-
2002	0.67	1.26	0.11	0.55	1.03	-	1.49	3.01	-
2003	0.66	1.25	-	0.59	1.09	-	1.47	3.09	-
2004	0.68	1.31	-	0.58	1.11	-	1.63	3.26	-
2005	0.74	1.39	0.12	0.56	1.06	-	1.92	3.77	-
2006	0.56	1.10	-	0.48	0.91	-	1.26	2.63	-
2007	0.63	1.21	-	0.52	0.97	-	1.43	2.97	-
1975-2007	1.84	3.62	0.13	1.91	3.73	0.12	2.22	4.53	0.24

^a SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).
Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 10.5
Kaposi Sarcoma

SEER Incidence^a Rates, Age-Adjusted and Age-Specific Rates, by Race and Sex

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>SEER Incidence</u>									
<u>Age at Diagnosis</u>									
Age-Adjusted Rates, 2003-2007									
All ages	0.6	1.2	0.1	0.6	1.0	0.1	1.2	2.4	0.2
Under 65	0.5	1.1	0.0	0.5	0.9	0.0	1.3	2.5	0.2
65 and over	1.1	1.9	0.6	1.1	1.9	0.5	0.9	1.5	-
All ages (IARC world std) ^b	0.5	0.9	0.1	0.4	0.8	0.0	1.0	1.9	0.1
Age-Specific Rates, 2003-2007									
<1	-	-	-	-	-	-	-	-	-
1-4	-	-	-	-	-	-	-	-	-
5-9	-	-	-	-	-	-	-	-	-
10-14	-	-	-	-	-	-	-	-	-
15-19	-	-	-	-	-	-	-	-	-
20-24	0.2	0.3	-	0.1	0.2	-	0.6	1.2	-
25-29	0.5	1.0	-	0.4	0.7	-	1.7	3.2	-
30-34	0.8	1.6	-	0.7	1.3	-	2.4	4.8	-
35-39	1.4	2.7	-	1.2	2.3	-	3.5	6.9	-
40-44	1.4	2.7	-	1.2	2.4	-	3.3	6.5	-
45-49	0.9	1.8	-	0.9	1.7	-	1.5	3.0	-
50-54	0.6	1.3	-	0.6	1.2	-	1.2	2.6	-
55-59	0.5	1.0	-	0.5	1.0	-	0.8	-	-
60-64	0.5	0.8	-	0.4	0.8	-	-	-	-
65-69	0.6	1.0	-	0.6	1.0	-	-	-	-
70-74	0.8	1.3	0.3	0.8	1.5	-	-	-	-
75-79	1.3	2.3	0.5	1.2	2.2	0.5	-	-	-
80-84	1.6	2.4	1.1	1.5	2.4	1.0	-	-	-
85+	2.1	4.0	1.3	2.1	3.9	1.3	-	-	-

^a SEER 17 areas. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130), unless noted.

^b Rates are per 100,000 and are age-adjusted to the IARC world standard population.

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 10.6
Kaposi Sarcoma

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	-	-	-	-	-	-
1970-1973 ^a	-	-	-	-	-	-	-	-	-
1975-1977 ^b	83.2 ^f	82.6 ^f	-	82.5 ^f	80.6 ^f	-	-	-	-
1978-1980 ^b	78.7 ^f	80.4 ^f	72.6 ^g	78.0 ^f	78.9 ^f	72.3 ^g	-	-	-
1981-1983 ^b	33.6	30.9	74.0 ^g	31.9	29.3	72.1 ^g	-	-	-
1984-1986 ^b	12.3	11.1	71.6 ^g	12.0	10.8	70.4 ^g	16.3	15.2	-
1987-1989 ^b	9.6	9.0	65.9 ^g	9.2	8.7	71.5 ^g	11.7	10.6	-
1990-1992 ^b	9.1	8.4	51.8 ^f	8.6	8.0	51.6 ^f	11.4	10.5	-
1993-1995 ^b	21.2	20.7	48.6 ^f	21.7	21.2	58.5 ^g	16.1	15.4	-
1996-1998 ^b	51.0	50.4	64.6 ^f	55.4	54.5	81.4 ^g	37.8	37.4	-
1999-2006 ^b	60.6 ^e	60.2 ^e	65.7 ^f	68.8 ^e	67.8 ^e	80.2 ^f	43.4	43.9	33.6 ^g
5-Year Period Survival (Percent) ^{cd}									
Year of Diagnosis:									
1999-2006	64.9	64.5	70.3	69.7	69.0	76.6	46.9	47.3	-
5-Year Relative Survival (Percent), 1999-2006 ^c									
Age at Diagnosis:									
Ages <45	57.7	58.1	40.2 ^f	62.2	62.2	-	44.1	45.2	16.5 ^f
Ages 45-54	57.6	58.6	-	59.6	60.5	-	44.2 ^f	45.4 ^f	-
Ages 55-64	74.8	75.4	-	77.1	77.3	-	51.9 ^g	51.4 ^g	-
Ages 65-74	77.9	80.0	69.0 ^f	76.1	78.1 ^f	68.8 ^g	-	-	-
Ages 75+	86.6 ^f	84.2 ^f	80.3 ^f	89.6 ^f	86.2 ^f	82.8 ^f	-	-	-
Ages <65	59.0	59.5	41.0 ^f	63.0	63.1	56.2 ^g	44.5	45.5	19.9 ^f
Ages 65+	83.1	82.8	79.5	83.9	82.5	81.5	73.5 ^g	-	-

^a Based on End Results data from a series of hospital registries and one population-based registry.
^b Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2007.
^c Based on the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2006. The remaining 13 SEER Areas contribute cases for the entire period 1999-2006. Based on follow-up of patients into 2007.
^d Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2004-2006: 0-1 year survival), (2003-2005: 1-2 year survival), (2002-2004: 2-3 year survival), (2001-2003: 3-4 year survival), (2000-2002: 4-5 years survival).
^e The difference between 1975-1977 and 1999-2006 is statistically significant (p<.05).
^f The standard error is between 5 and 10 percentage points.
^g The standard error is greater than 10 percentage points.
- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 10.7
Kaposi Sarcoma

SEER^a Relative Survival (Percent)
By Year of Diagnosis

All Races, Males and Females

Survival Time	Year of Diagnosis																			
	1975- 1979	1980- 1984	1985- 1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
1-year	95.7	66.8	60.2	61.9	62.8	63.3	59.1	55.8	62.2	69.6	73.7	73.9	76.7	74.2	80.1	77.8	74.8	82.4	81.7	80.1
2-year	90.4	44.3	33.9	33.3	30.4	28.6	30.1	27.7	46.8	60.2	64.3	64.9	65.0	67.2	72.7	71.0	71.9	73.6	78.2	
3-year	89.6	35.0	20.0	19.8	15.5	16.5	19.4	20.9	42.5	54.1	60.8	60.1	61.0	60.5	67.0	65.9	66.2	70.1		
4-year	85.0	30.2	13.7	14.3	10.9	11.0	15.1	18.4	38.3	50.9	56.9	57.5	56.0	56.2	63.9	64.4	64.3			
5-year	85.0	26.1	10.1	9.7	8.5	9.0	13.5	17.2	35.1	47.5	54.5	56.6	55.0	53.1	63.0	57.3				
6-year	80.2	22.1	8.4	7.5	7.5	8.4	13.0	16.0	34.4	44.8	52.0	53.2	52.2	51.4	62.1					
7-year	78.6	20.6	7.1	7.0	7.1	7.6	12.2	14.8	32.7	43.8	47.4	50.2	51.5	51.3						
8-year	78.6	17.5	6.1	6.3	6.6	7.4	11.6	14.4	31.4	43.5	44.3	47.9	50.8							
9-year	78.6	15.8	5.4	6.1	6.1	7.3	11.2	13.6	30.2	41.6	40.7	46.6								
10-year	78.6	13.7	5.0	5.9	5.9	6.9	10.9	13.4	28.9	41.4	39.8									
11-year	78.4	12.3	4.6	5.6	5.7	6.9	10.3	13.0	27.7	40.8										
12-year	78.4	11.8	4.4	5.6	5.6	6.8	10.1	12.9	26.8											
13-year	78.4	10.8	4.0	5.5	5.3	6.7	10.0	12.8												
14-year	78.4	10.7	3.7	4.9	5.2	6.4	9.9													
15-year	78.4	10.1	3.6	4.3	5.1	6.1														
16-year	78.4	9.5	3.4	4.1	4.9															
17-year	78.4	8.9	3.3	4.0																
18-year	78.4	7.7	3.2																	
19-year	78.4	7.7																		
20-year	78.4	7.2																		

^a Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 10.8
Kaposi Sarcoma

SEER^a Relative Survival (Percent)
By Year of Diagnosis

All Races, Males

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
Survival Time																				
1-year	95.9	65.1	59.8	61.5	62.3	63.1	58.9	55.2	61.4	69.4	73.7	73.0	76.7	73.6	79.3	76.6	75.0	81.2	82.6	79.4
2-year	90.2	41.7	33.2	32.9	29.6	28.2	29.2	27.1	45.6	59.7	64.0	63.2	64.4	65.8	73.1	70.0	71.6	72.4	78.8	
3-year	88.4	32.6	19.2	19.1	14.6	16.1	18.7	20.4	41.7	53.9	60.2	58.5	60.5	59.6	68.3	65.3	66.1	68.6		
4-year	85.8	27.8	12.9	13.6	9.9	10.7	14.4	17.9	37.5	50.6	56.1	55.5	55.0	56.0	64.6	64.7	63.9			
5-year	85.8	24.0	9.4	9.0	7.6	8.7	12.8	16.7	34.8	47.4	54.6	54.3	53.8	53.2	63.3	57.4				
6-year	77.8	20.0	7.7	7.0	6.6	8.1	12.3	15.6	34.1	44.7	51.8	51.8	50.6	51.9	62.8					
7-year	76.9	18.3	6.4	6.4	6.2	7.3	11.7	14.5	32.3	43.7	47.7	49.8	49.6	51.7						
8-year	76.9	15.8	5.5	5.8	5.7	7.2	11.1	14.1	31.0	43.4	44.4	48.4	49.4							
9-year	76.9	14.3	4.9	5.5	5.1	7.1	10.8	13.4	30.0	41.4	40.9	47.0								
10-year	76.9	12.4	4.6	5.4	5.0	6.7	10.5	13.1	28.8	41.2	39.9									
11-year	72.7	11.0	4.3	5.3	4.8	6.7	9.9	12.7	27.7	40.7										
12-year	72.7	10.6	4.1	5.3	4.6	6.6	9.7	12.6	26.8											
13-year	72.7	9.8	3.8	5.1	4.3	6.5	9.6	12.5												
14-year	72.7	9.6	3.6	4.5	4.3	6.2	9.5													
15-year	72.7	8.9	3.5	4.2	4.3	5.9														
16-year	72.7	8.6	3.3	4.0	4.0															
17-year	72.7	8.3	3.3	3.9																
18-year	72.7	7.4	3.2																	
19-year	72.7	7.4																		
20-year	72.7	6.9																		

^a Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 10.9
Kaposi Sarcoma

SEER^a Relative Survival (Percent)
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
Survival Time																				
1-year	93.8	91.8	83.7	79.8	90.1	74.7	70.9	82.3	87.5	77.7	72.4	86.8	75.5	81.2	87.1	88.8	69.3	100.0	64.6	89.8
2-year	90.6	86.2	78.8	55.6	79.9	53.6	70.9	56.5	85.4	77.7	67.1	86.8	69.5	81.2	68.2	80.4	69.3	96.8	64.6	
3-year	90.6	76.1	74.1	55.6	75.6	43.2	50.7	48.4	72.4	62.6	67.1	86.8	65.4	72.4	52.8	70.2	64.5	96.8		
4-year	82.9	72.8	73.3	49.9	75.6	31.9	50.7	43.7	66.7	62.6	67.1	86.8	65.4	60.5	52.8	60.5	64.5			
5-year	81.0	66.7	72.7	47.6	74.8	31.9	50.7	43.7	46.5	51.3	53.8	86.8	65.4	52.0	52.8	54.2				
6-year	81.0	65.0	72.7	42.9	71.4	26.9	50.7	40.6	46.5	44.2	53.8	80.1	65.4	42.8	49.1					
7-year	81.0	65.0	69.6	42.9	71.4	26.9	44.5	35.2	46.5	44.2	41.5	57.0	65.4	42.8						
8-year	81.0	58.9	60.9	42.9	71.4	22.1	44.5	35.2	46.5	44.2	41.5	30.3	65.4							
9-year	81.0	56.4	58.9	42.9	71.4	22.1	40.6	30.7	38.8	44.2	34.6	30.3								
10-year	81.0	50.9	50.8	39.0	71.4	22.1	40.6	30.7	35.3	44.2	34.6									
11-year	81.0	48.5	44.0	33.9	71.4	22.1	40.6	30.7	29.6	42.4										
12-year	81.0	48.5	35.9	33.9	71.4	22.1	37.7	30.7	29.6											
13-year	81.0	48.5	31.1	33.9	71.4	22.1	37.7	30.7												
14-year	81.0	48.5	21.5	33.9	71.4	22.1	37.7													
15-year	81.0	48.5	17.7	13.6	71.4	22.1														
16-year	81.0	48.5	17.7	13.6	71.4															
17-year	81.0	37.7	16.1	13.6																
18-year	81.0	21.3	16.1																	
19-year	81.0	21.3																		
20-year	81.0	21.3																		

^a Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 10.10
Kaposi Sarcoma

Risk of Being Diagnosed With Cancer in 10, 20 and 30 Years,
Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age, and
Lifetime Risk of Dying from Cancer Given Alive at Current Age
Both Sexes, 2005-2007 By Race/Ethnicity

Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer	Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer
		+10 yrs	+20 yrs	+30 yrs	Ever				+10 yrs	+20 yrs	+30 yrs	Ever	
All Races	0	0.00	0.00	0.00	0.05	0.00	Asian/ Pacific Islander	0	0.00	0.00	0.00	0.02	0.00
	10	0.00	0.00	0.01	0.05	0.00		10	0.00	0.00	0.00	0.02	0.00
	20	0.00	0.01	0.02	0.05	0.00		20	0.00	0.00	0.01	0.02	0.00
	30	0.01	0.02	0.03	0.05	0.00		30	0.00	0.01	0.01	0.02	0.00
	40	0.01	0.02	0.02	0.04	0.00		40	0.00	0.01	0.01	0.02	0.00
	50	0.01	0.01	0.02	0.03	0.00		50	0.00	0.00	0.01	0.02	0.00
	60	0.00	0.01	0.02	0.02	0.00		60	0.00	0.01	0.01	0.01	0.00
	70	0.01	0.02	-	0.02	0.00		70	0.01	0.01	-	0.01	0.00
80	0.01	-	-	0.02	0.00	80	0.01	-	-	0.01	0.00		
White	0	0.00	0.00	0.00	0.04	0.00	American Indian/ Alaska Native ^a	0	0.00	0.00	0.00	0.03	0.00
	10	0.00	0.00	0.01	0.04	0.00		10	0.00	0.00	0.00	0.03	0.00
	20	0.00	0.01	0.02	0.04	0.00		20	0.00	0.00	0.01	0.03	0.00
	30	0.01	0.02	0.02	0.04	0.00		30	0.00	0.01	0.02	0.03	0.00
	40	0.01	0.01	0.02	0.03	0.00		40	0.01	0.02	0.02	0.03	0.00
	50	0.00	0.01	0.02	0.02	0.00		50	0.01	0.01	0.02	0.02	0.00
	60	0.00	0.01	0.02	0.02	0.00		60	0.00	0.01	0.01	0.01	0.00
	70	0.01	0.02	-	0.02	0.00		70	0.01	0.01	-	0.01	0.00
80	0.01	-	-	0.02	0.00	80	0.00	-	-	0.00	0.00		
Black	0	0.00	0.00	0.01	0.08	0.01	Hispanic ^b	0	0.00	0.00	0.00	0.09	0.01
	10	0.00	0.01	0.04	0.09	0.01		10	0.00	0.00	0.02	0.09	0.01
	20	0.01	0.04	0.06	0.09	0.01		20	0.00	0.02	0.03	0.09	0.01
	30	0.03	0.05	0.06	0.07	0.01		30	0.01	0.02	0.03	0.08	0.01
	40	0.02	0.03	0.04	0.05	0.01		40	0.01	0.02	0.03	0.07	0.00
	50	0.01	0.01	0.02	0.03	0.00		50	0.01	0.01	0.03	0.06	0.00
	60	0.01	0.01	0.02	0.02	0.00		60	0.01	0.02	0.04	0.06	0.00
	70	0.01	0.01	-	0.02	0.00		70	0.01	0.04	-	0.05	0.00
80	0.01	-	-	0.01	0.00	80	0.03	-	-	0.05	0.00		

Devcan Version 6.5.0, June 2010, National Cancer Institute (<http://srab.cancer.gov/devcan/>).

Source: Incidence data are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Mortality data are from the NCHS public use data file for the total US.

^a Underlying incidence and mortality data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

Underlying mortality data for Hispanics exclude deaths from the District of Columbia, Minnesota, New Hampshire and North Dakota.

- Statistic could not be calculated.

A percent of 0.00 represents a value that is below 0.005.

Table 10.11
Kaposi Sarcoma

Risk of Being Diagnosed With Cancer in 10, 20 and 30 Years,
Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age, and
Lifetime Risk of Dying from Cancer Given Alive at Current Age
Males, 2005-2007 By Race/Ethnicity

Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer	Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer
		+10 yrs	+20 yrs	+30 yrs	Ever				+10 yrs	+20 yrs	+30 yrs	Ever	
All Races	0	0.00	0.00	0.01	0.08	0.01	Asian/ Pacific Islander	0	0.00	0.00	0.00	0.04	0.00
	10	0.00	0.01	0.03	0.09	0.01		10	0.00	0.00	0.00	0.04	0.00
	20	0.01	0.03	0.05	0.09	0.01		20	0.00	0.00	0.01	0.04	0.00
	30	0.02	0.04	0.05	0.08	0.01		30	0.00	0.01	0.01	0.04	0.00
	40	0.02	0.03	0.04	0.06	0.00		40	0.01	0.01	0.02	0.04	0.00
	50	0.01	0.02	0.03	0.04	0.00		50	0.00	0.01	0.02	0.03	0.00
	60	0.01	0.02	0.03	0.03	0.00		60	0.01	0.02	0.03	0.03	0.00
	70	0.01	0.03	-	0.03	0.00		70	0.01	0.02	-	0.02	0.00
80	0.02	-	-	0.02	0.00	80	0.02	-	-	0.02	0.00		
White	0	0.00	0.00	0.00	0.08	0.00	American Indian/ Alaska Native ^a	0	0.00	0.00	0.00	0.04	0.00
	10	0.00	0.00	0.02	0.08	0.00		10	0.00	0.00	0.01	0.04	0.00
	20	0.00	0.02	0.04	0.08	0.00		20	0.00	0.01	0.03	0.04	0.00
	30	0.02	0.03	0.04	0.07	0.00		30	0.01	0.03	0.04	0.04	0.00
	40	0.02	0.03	0.04	0.06	0.00		40	0.02	0.03	0.03	0.03	0.00
	50	0.01	0.02	0.03	0.04	0.00		50	0.01	0.01	0.01	0.01	0.00
	60	0.01	0.02	0.03	0.03	0.00		60	0.00	0.00	0.00	0.00	0.00
	70	0.01	0.02	-	0.03	0.00		70	0.00	0.00	-	0.00	0.00
80	0.02	-	-	0.02	0.00	80	0.00	-	-	0.00	0.00		
Black	0	0.00	0.00	0.02	0.15	0.02	Hispanic ^b	0	0.00	0.00	0.01	0.15	0.01
	10	0.00	0.02	0.07	0.16	0.02		10	0.00	0.01	0.03	0.15	0.01
	20	0.02	0.07	0.12	0.16	0.02		20	0.01	0.03	0.05	0.15	0.01
	30	0.05	0.10	0.12	0.14	0.01		30	0.02	0.05	0.06	0.15	0.01
	40	0.05	0.07	0.07	0.09	0.01		40	0.02	0.04	0.05	0.13	0.01
	50	0.02	0.03	0.04	0.04	0.00		50	0.01	0.03	0.05	0.11	0.01
	60	0.01	0.02	0.02	0.03	0.00		60	0.01	0.04	0.07	0.10	0.01
	70	0.02	0.02	-	0.03	0.00		70	0.02	0.07	-	0.10	0.01
80	0.01	-	-	0.02	0.00	80	0.06	-	-	0.10	0.01		

Devcan Version 6.5.0, June 2010, National Cancer Institute (<http://srab.cancer.gov/devcan/>).

Source: Incidence data are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Mortality data are from the NCHS public use data file for the total US.

^a Underlying incidence and mortality data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

Underlying mortality data for Hispanics exclude deaths from the District of Columbia, Minnesota, New Hampshire and North Dakota.

- Statistic could not be calculated.

A percent of 0.00 represents a value that is below 0.005.

Table 10.12
Kaposi Sarcoma

Risk of Being Diagnosed With Cancer in 10, 20 and 30 Years,
Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age, and
Lifetime Risk of Dying from Cancer Given Alive at Current Age
Females, 2005-2007 By Race/Ethnicity

Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer	Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer
		+10 yrs	+20 yrs	+30 yrs	Ever				+10 yrs	+20 yrs	+30 yrs	Ever	
All Races	0	0.00	0.00	0.00	0.01	0.00	Asian/ Pacific Islander	0	0.00	0.00	0.00	0.00	0.00
	10	0.00	0.00	0.00	0.01	0.00		10	0.00	0.00	0.00	0.00	0.00
	20	0.00	0.00	0.00	0.01	0.00		20	0.00	0.00	0.00	0.00	0.00
	30	0.00	0.00	0.00	0.01	0.00		30	0.00	0.00	0.00	0.00	0.00
	40	0.00	0.00	0.00	0.01	0.00		40	0.00	0.00	0.00	0.00	0.00
	50	0.00	0.00	0.00	0.01	0.00		50	0.00	0.00	0.00	0.00	0.00
	60	0.00	0.00	0.01	0.01	0.00		60	0.00	0.00	0.00	0.00	0.00
	70	0.00	0.01	-	0.01	0.00		70	0.00	0.00	-	0.00	0.00
80	0.01	-	-	0.01	0.00	80	0.00	-	-	0.00	0.00		
White	0	0.00	0.00	0.00	0.01	0.00	American Indian/ Alaska Native ^a	0	0.00	0.00	0.00	0.02	0.00
	10	0.00	0.00	0.00	0.01	0.00		10	0.00	0.00	0.00	0.02	0.00
	20	0.00	0.00	0.00	0.01	0.00		20	0.00	0.00	0.00	0.02	0.00
	30	0.00	0.00	0.00	0.01	0.00		30	0.00	0.00	0.00	0.02	0.00
	40	0.00	0.00	0.00	0.01	0.00		40	0.00	0.00	0.00	0.02	0.00
	50	0.00	0.00	0.00	0.01	0.00		50	0.00	0.00	0.02	0.02	0.00
	60	0.00	0.00	0.01	0.01	0.00		60	0.00	0.02	0.02	0.02	0.00
	70	0.00	0.01	-	0.01	0.00		70	0.02	0.02	-	0.02	0.00
80	0.01	-	-	0.01	0.00	80	0.00	-	-	0.00	0.00		
Black	0	0.00	0.00	0.00	0.02	0.00	Hispanic ^b	0	0.00	0.00	0.00	0.03	0.00
	10	0.00	0.00	0.01	0.02	0.00		10	0.00	0.00	0.00	0.03	0.00
	20	0.00	0.01	0.01	0.02	0.00		20	0.00	0.00	0.00	0.03	0.00
	30	0.00	0.01	0.01	0.02	0.00		30	0.00	0.00	0.00	0.03	0.00
	40	0.00	0.00	0.01	0.02	0.00		40	0.00	0.00	0.00	0.03	0.00
	50	0.00	0.01	0.01	0.01	0.00		50	0.00	0.00	0.01	0.03	0.00
	60	0.00	0.01	0.01	0.01	0.00		60	0.00	0.01	0.02	0.03	0.00
	70	0.01	0.01	-	0.01	0.00		70	0.01	0.02	-	0.03	0.00
80	0.00	-	-	0.00	0.00	80	0.02	-	-	0.02	0.00		

Devcan Version 6.5.0, June 2010, National Cancer Institute (<http://srab.cancer.gov/devcan/>).

Source: Incidence data are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Mortality data are from the NCHS public use data file for the total US.

^a Underlying incidence and mortality data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

Underlying mortality data for Hispanics exclude deaths from the District of Columbia, Minnesota, New Hampshire and North Dakota.

- Statistic could not be calculated.

A percent of 0.00 represents a value that is below 0.005.

Table 10.13
Kaposi Sarcoma

SEER Incidence
Age-Adjusted Rates and Trends^a
By Race/Ethnicity and Sex

SEER Incidence	SEER 17 Areas ^b			SEER 13 Areas ^b			SEER 9 Areas ^b		
	Rate 2003-2007			Trend 1998-2007 ^c			Trend 1998-2007 ^d		
	Rate per 100,000 persons			AAPC (%)			AAPC (%)		
RACE/ETHNICITY	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Races	0.6	1.2	0.1	-3.3*	-3.2*	-6.4*	-2.3	-2.5	-6.1*
White	0.6	1.0	0.1	-3.0*	-2.9*	-	-2.1	-2.3	-5.3*
White Hispanic ^e	0.9	1.6	0.2	-3.3	-2.3	-	-	-	-
White Non-Hispanic ^e	0.5	0.9	0.1	-3.2	-3.3	-	-	-	-
Black	1.2	2.4	0.2	-4.7*	-4.5*	-	-4.0*	-3.7	-
Asian/Pacific Islander	0.2	0.4	-	-	-	-	-	-	-
Amer Ind/Alaska Nat ^f	-	-	-	-	-	-	-	-	-
Hispanic ^e	0.9	1.6	0.2	-3.7	-2.5	-	-	-	-

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute.

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

^a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130). Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia.

The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.

^c The 1998-2007 AAPC estimates are based on a Joinpoint analysis with up to 2 Joinpoints over diagnosis years 1992-2007.

^d The 1998-2007 AAPC estimates are based on a Joinpoint analysis with up to 4 Joinpoints over diagnosis years 1975-2007.

^e Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^f Incidence data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

* The APC is significantly different from zero (p<.05).

Table 10.14
Kaposi Sarcoma

Age-Adjusted SEER Incidence Rates^a
By Registry, Race and Sex

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>SEER Incidence Rates^a, 2003-2007</u>									
Atlanta & Rural Georgia	1.32	2.60	-	0.88	1.64	-	2.04	4.38	-
Atlanta	1.35	2.66	-	0.89	1.66	-	2.11	4.54	-
Rural Georgia	-	-	-	-	-	-	-	-	-
California	0.75	1.43	0.10	0.75	1.43	0.08	1.31	2.46	-
Greater Bay Area	1.00	1.91	0.11	1.16	2.20	-	2.08	3.90	-
San Francisco-Oakland	1.30	2.49	0.14	1.54	2.93	-	2.20	4.21	-
San Jose-Monterey	0.46	0.88	-	0.51	0.98	-	-	-	-
Los Angeles	1.09	2.15	0.11	1.16	2.24	0.11	1.25	2.61	-
Greater California	0.49	0.89	0.09	0.45	0.82	0.07	1.07	1.79	-
Connecticut	0.40	0.72	-	0.33	0.60	-	1.04	-	-
Detroit	0.44	0.80	-	0.24	0.41	-	0.83	1.74	-
Hawaii	0.47	0.88	-	1.14	1.98	-	-	-	-
Iowa	0.11	-	-	-	-	-	-	-	-
Kentucky	0.21	0.38	-	0.19	0.34	-	-	-	-
Louisiana	0.55	0.94	0.20	0.44	0.74	-	0.79	1.40	-
New Jersey	0.55	1.03	0.14	0.44	0.83	0.12	1.13	2.16	-
New Mexico	0.42	0.81	-	0.42	0.80	-	-	-	-
Seattle-Puget Sound	0.49	0.95	-	0.45	0.86	-	-	-	-
Utah	0.26	0.48	-	0.27	0.49	-	-	-	-
9 SEER Areas ^b	0.66	1.25	0.08	0.55	1.03	0.08	1.54	3.15	-
11 SEER Areas ^b	0.74	1.44	0.09	0.68	1.30	0.08	1.48	3.03	0.14
13 SEER Areas ^b	0.74	1.43	0.09	0.68	1.30	0.08	1.47	2.99	0.14
17 SEER Areas ^b	0.62	1.17	0.10	0.55	1.04	0.09	1.23	2.40	0.20

^a Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

^b The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

The SEER 11 areas comprise the SEER 9 areas plus San Jose-Monterey and Los Angeles.

The SEER 13 areas comprise the SEER 11 areas plus the Alaska Native Registry and Rural Georgia.

The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 10.15
Kaposi SarcomaEstimated United States Cancer Prevalence Counts^a on January 1, 2007
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <17 ^e	0 to <32 ^e	>=32 ^g	Complete ^h
<u>Race</u>	<u>Sex</u>										
All Races ^b	Both Sexes	6,329	5,120	7,221	1,941	616	206	19,682	21,513	+	+
	Males	5,909	4,771	6,982	1,798	582	136	18,560	20,237	+	+
	Females	420	349	239	143	34	70	1,122	1,276	+	+
White ^b	Both Sexes	4,583	3,682	5,965	1,604	508	170	15,072	16,594	+	+
	Males	4,259	3,433	5,797	1,494	485	100	14,250	15,628	+	+
	Females	324	249	168	110	23	70	822	966	+	+
Black ^b	Both Sexes	1,483	1,113	863	155	63	12	3,537	3,689	+	+
	Males	1,404	1,047	803	145	63	12	3,322	3,474	+	+
	Females	79	66	60	10	0	0	215	215	+	+
Asian/ Pacific Islander ^c	Both Sexes	100	68	76	+	+	+	247	+	+	+
	Males	95	68	76	+	+	+	242	+	+	+
	Females	5	0	0	+	+	+	5	+	+	+
Hispanic ^d	Both Sexes	1,142	945	1,123	+	+	+	3,318	+	+	+
	Males	1,093	886	1,103	+	+	+	3,170	+	+	+
	Females	49	59	20	+	+	+	148	+	+	+

Estimated prevalence percent^a on January 1, 2007, of the SEER 11 population diagnosed in the previous 17 years
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)									Age-Adjusted ^f	
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races ^c	Both Sexes	0.0073%	-	-	0.0008%	0.0075%	0.0193%	0.0140%	0.0069%	0.0077%	0.0130%	0.0072%
	Males	0.0141%	-	-	0.0014%	0.0147%	0.0379%	0.0281%	0.0137%	0.0152%	0.0256%	0.0141%
	Females	0.0006%	-	-	-	-	0.0006%	0.0005%	0.0008%	0.0018%	0.0059%	0.0006%
White ^c	Both Sexes	0.0074%	-	-	0.0006%	0.0068%	0.0195%	0.0142%	0.0072%	0.0084%	0.0130%	0.0071%
	Males	0.0141%	-	-	0.0010%	0.0130%	0.0378%	0.0282%	0.0141%	0.0161%	0.0260%	0.0139%
	Females	0.0006%	-	-	-	-	0.0006%	0.0003%	0.0008%	0.0022%	0.0059%	0.0005%
Black ^c	Both Sexes	0.0097%	-	-	0.0026%	0.0161%	0.0275%	0.0175%	0.0070%	0.0045%	0.0105%	0.0101%
	Males	0.0195%	-	-	0.0047%	0.0347%	0.0576%	0.0364%	0.0153%	0.0096%	-	0.0208%
	Females	0.0008%	-	-	-	-	-	0.0017%	-	-	0.0107%	0.0009%
Asian/ Pacific Islander ^c	Both Sexes	0.0018%	-	-	-	0.0014%	0.0036%	0.0043%	0.0019%	0.0033%	0.0055%	0.0018%
	Males	0.0037%	-	-	-	0.0029%	0.0072%	0.0092%	0.0042%	0.0078%	0.0122%	0.0038%
	Females	-	-	-	-	-	-	-	-	-	-	-
Hispanic ^d	Both Sexes	0.0073%	-	-	0.0011%	0.0095%	0.0236%	0.0152%	0.0103%	0.0140%	0.0318%	0.0096%
	Males	0.0136%	-	-	0.0019%	0.0175%	0.0450%	0.0305%	0.0206%	0.0287%	0.0632%	0.0187%
	Females	0.0006%	-	-	-	-	-	-	-	-	0.0136%	0.0010%

^a US 2007 cancer prevalence counts are based on 2007 cancer prevalence proportions from the SEER registries and 1/1/2007 US population estimates based on the average of 2006 and 2007 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

^{b c d} Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia.

^e Maximum limited-duration prevalence: 32 years for 1975-2007 SEER 9 data; 17 years for 1990-2007 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

^f Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.


^{g h i} (g) Cases diagnosed more than 32 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <32 and >=32. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Figure 10.1

All Cancer Sites vs Kaposi Sarcoma SEER Incidence Rates, 1975-2007 Males, Ages 20-54



Source: SEER 9 areas. Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103). Regression lines are calculated using the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute.

All SEER excluding
San Francisco/Oakland
Males, Ages 20-54
1975-2007

San Francisco/Oakland
Males, Ages 20-54
1975-2007

San Francisco County/City
Males, Ages 20-54
1975-2007






Figure 10.2

Source: SEER 9 areas. Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

^a Kaposi Sarcoma cases are excluded from Colon & Rectum, Lung & Bronchus, and Non-Hodgkin Lymphoma cases.